Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 172Esophageal Neoplasms 161Esophageal Squamous Cell Carcinoma 116Cholangiocarcinoma 77Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Adenocarcinoma Of Esophagus 52Gallbladder Neoplasms 39Colorectal Neoplasms 36Neoplasm Metastasis 30Carcinoma, Non-Small-Cell Lung 28Carcinoma, Hepatocellular 28Neoplasms 27Bile Duct Neoplasms 24Ovarian Neoplasms 19Liver Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Colonic Neoplasms 13Peritoneal Neoplasms 12Gastrointestinal Neoplasms 12Anus Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Adenocarcinoma 11Rectal Neoplasms 9Melanoma 9Lung Neoplasms 9Carcinoma, Squamous Cell 9Breast Neoplasms 9Sarcoma 8Hepatoblastoma 8

Interventions

Gemcitabine 13Albumin-Bound Paclitaxel 8Taxes 6130-nm albumin-bound paclitaxel 6Fluorouracil 5Oxaliplatin 4dehydroftorafur 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Leucovorin 3Irinotecan 3Losartan 2Cisplatin 2tocilizumab 1selicrelumab 1niraparib 1irinotecan sucrosofate 1indusatumab 1folfirinox 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1S 1 (combination) 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Cisplatin × Gastrointestinal × Clear all
NCT06095141 2025-08-07

PTCA199-6

Fudan University

Phase 2/3 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02550327 2021-06-22

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Baylor Research Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡